AbbVie (ABBV) Total Current Liabilities (2012 - 2026)

AbbVie has disclosed Total Current Liabilities across 15 years of filings, most recently posting $42.1 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 15.65% year-over-year to $42.1 billion; the TTM figure through Mar 2026 stood at $42.1 billion (up 15.65% YoY), while the FY2025 annual figure was $43.3 billion, up 11.72% from the prior year.
• Total Current Liabilities eased to $42.1 billion in Q1 2026, from $43.3 billion in the prior quarter.
• Over the last five years, Total Current Liabilities for ABBV reached as high as $43.3 billion in Q4 2025 and fell as low as $27.6 billion in Q1 2023.
• The 5-year median for Total Current Liabilities is $37.8 billion (2023), against an average of $36.9 billion.
• Annual changes were most pronounced in 2022 — Total Current Liabilities retreated 16.07% — and 2024, when it jumped 50.5%.
• A 5-year view of Total Current Liabilities shows it stood at $29.5 billion in 2022, then increased by 28.11% to $37.8 billion in 2023, then grew by 2.4% to $38.7 billion in 2024, then grew by 11.72% to $43.3 billion in 2025, then retreated by 2.75% to $42.1 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $42.1 billion, $43.3 billion, and $39.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.